02 | MD Anderson Cancer Center

Osteosarcoma profiling reveals why immunotherapy remains ineffective

February 21, 2020

Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally poor responses observed from treatment with immune checkpoint inhibitors, according to new research from The University of Texas MD Anderson Cancer Center.

The study, published today in Nature Communications, found that poor infiltration of the tumor by immune cells, low activity from available...

MD Anderson announces strategic collaboration with Denali Therapeutics to research and develop targeted therapies for neurodegenerative diseases

BY Kelly Calagna

February 20, 2020

The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration with Denali Therapeutics Inc. to develop...

MD Anderson receives more than $20 million in CPRIT funding

February 19, 2020

The University of Texas MD Anderson Cancer Center today was awarded more than $20 million from the Cancer Prevention and Research Institute...

Houston Dash join Dynamo, MD Anderson in Making Cancer History

February 19, 2020

The University of Texas MD Anderson Cancer Center today announced the Houston Dash will join the institution's efforts toward one goal: end cancer. Beginning with the 2020 season, MD Anderson will serve as the official cancer center and jersey partner of the Houston Dash from the National Women's Soccer League (NWSL) and continue to serve in the same role for the two-time Major League Soccer (MLS) champion Houston Dynamo. The...